MicroRNA-29 family inhibits rhabdomyosarcoma formation and progression by regulating GEFT function
AJTR Copyright © 2020..
The microRNA-29 family, which contains mir-29a, mir-29b, and mir-29c, can promote or resist the development of several types of tumors. However, its role in rhabdomyosarcoma (RMS) has not been determined. In this work, we detected the expression of mir-29a/b/c in RMS. Results showed that the tissues and cell lines in RMS were significantly lower than those in muscle and human skeletal muscle cells, and that these cell lines could also inhibit the proliferation, migration, and invasion and induce apoptosis of RMS cells. Dual-luciferase reporter assay and RNA immunoprecipitation verified the direct binding site between mir-29a/b/c and GEFT. Under the combined actions of mir-29a/b/c and GEFT, the former weakened the promoting effect of GEFT on RMS cells. Finally, mir-29a inhibited the tumorigenesis of subcutaneous xenografts in nude mice and inhibited the mRNA and protein expression levels of GEFT in transplanted tumors. These findings proved that mir-29 inhibits the occurrence of RMS and may be a potential molecular target.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
American journal of translational research - 12(2020), 3 vom: 30., Seite 1136-1154 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Yang [VerfasserIn] |
|---|
| Themen: |
Apoptosis |
|---|
| Anmerkungen: |
Date Revised 28.09.2020 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM308549317 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM308549317 | ||
| 003 | DE-627 | ||
| 005 | 20231225131951.0 | ||
| 007 | tu | ||
| 008 | 231225s2020 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1028.xml |
| 035 | |a (DE-627)NLM308549317 | ||
| 035 | |a (NLM)32269740 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Yang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a MicroRNA-29 family inhibits rhabdomyosarcoma formation and progression by regulating GEFT function |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Revised 28.09.2020 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a AJTR Copyright © 2020. | ||
| 520 | |a The microRNA-29 family, which contains mir-29a, mir-29b, and mir-29c, can promote or resist the development of several types of tumors. However, its role in rhabdomyosarcoma (RMS) has not been determined. In this work, we detected the expression of mir-29a/b/c in RMS. Results showed that the tissues and cell lines in RMS were significantly lower than those in muscle and human skeletal muscle cells, and that these cell lines could also inhibit the proliferation, migration, and invasion and induce apoptosis of RMS cells. Dual-luciferase reporter assay and RNA immunoprecipitation verified the direct binding site between mir-29a/b/c and GEFT. Under the combined actions of mir-29a/b/c and GEFT, the former weakened the promoting effect of GEFT on RMS cells. Finally, mir-29a inhibited the tumorigenesis of subcutaneous xenografts in nude mice and inhibited the mRNA and protein expression levels of GEFT in transplanted tumors. These findings proved that mir-29 inhibits the occurrence of RMS and may be a potential molecular target | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a GEFT | |
| 650 | 4 | |a Rhabdomyosarcoma | |
| 650 | 4 | |a apoptosis | |
| 650 | 4 | |a invasion | |
| 650 | 4 | |a migration | |
| 650 | 4 | |a mir-29a/b/c | |
| 650 | 4 | |a proliferation | |
| 700 | 1 | |a Zhang, Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Pang, Yuweng |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Lingxie |e verfasserin |4 aut | |
| 700 | 1 | |a Shang, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Zhenzhen |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Qianqian |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yangyang |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xiaomeng |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Qianru |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Qiaochu |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Chunxia |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Feng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of translational research |d 2009 |g 12(2020), 3 vom: 30., Seite 1136-1154 |w (DE-627)NLM193229463 |x 1943-8141 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2020 |g number:3 |g day:30 |g pages:1136-1154 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2020 |e 3 |b 30 |h 1136-1154 | ||